Investigational Drug Information for Narlaprevir
✉ Email this page to a colleague
What is the drug development status for Narlaprevir?
Narlaprevir is an investigational drug.
There have been 7 clinical trials for Narlaprevir.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 7th 2014.
The most common disease conditions in clinical trials are Hepatitis C, Chronic, Hepatitis C, and Hepatitis. The leading clinical trial sponsors are R-Pharm, Almedis, and Merck Sharp & Dohme Corp.
Summary for Narlaprevir
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 378 |
| WIPO Patent Applications | 238 |
| Japanese Patent Applications | 96 |
| Clinical Trial Progress | Phase 3 (2014-05-07) |
| Vendors | 36 |
Recent Clinical Trials for Narlaprevir
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 | Almedis | Phase 2 |
| Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 | ChromSystemsLab | Phase 2 |
| Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 | Scientific Center EFiS | Phase 2 |
Clinical Trial Summary for Narlaprevir
Top disease conditions for Narlaprevir
Top clinical trial sponsors for Narlaprevir
US Patents for Narlaprevir
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
